New drug combo aims to control aggressive blood cancer
NCT ID NCT05268003
Summary
This study is testing whether adding the drug ponatinib to a specific chemotherapy regimen and another drug called venetoclax can help patients whose T-cell acute lymphoblastic leukemia has returned or not responded to prior treatment. It aims to see if this combination can put the cancer into remission. The trial is for patients aged 12 and older who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.